Cynthia A. Jackevicius
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cynthia A. Jackevicius has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Jack V. Tu
Faculty of Medicine, University of Toronto, Institute for Clinical Evaluative Sciences, Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
3 shared publications Paul Daly
2 shared publicationsAlice Newman
1 shared publication- Angela M. Cheung
Institute of Medical Science, University of Toronto
1 shared publication Canadian Cardiovascular Outcomes Research Team
1 shared publicationDavid Alter
1 shared publication
Latest Publications
- 26 February 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 117 (8) , 1028-1036
Prevalence, Predictors, and Outcomes of Primary Nonadherence After Acute Myocardial Infarction
Background— Secondary prevention after acute myocardial infarction (AMI) is achieved primarily through medications. However, patients must take their medications to benefit. Medication adherence research has focused primarily on continuation of medications rather than not filling the first prescription written (primary nonadherence). Our objectives were to characterize, to determine factors of, and to measure outcomes associated with primary nonadherence after AMI. Methods and Results— We conducted a population-based cohort study using an AMI registry linked with administrative data in Ontario, Canada. The primary outcome was 1-year mortality. There were 4591 post-AMI patients >65 years of age included with 12 832 prescriptions written, of which 73% and 79% were filled within 7 and 120 days, respectively. By 120 days after discharge, more cardiac than noncardiac prescriptions were filled (82% versus 35%, respectively; P P =0.001) and none versus all (odds ratio, 1.80; 95% confidence interval, 1.35 to 2.42; P Conclusions— Patients fill most of their discharge prescriptions within 1 week after AMI. The 1-year mortality rate was higher for those patients who did not fill all of their discharge medications after AMI. Factors such as discharge medication counseling and postdischarge follow-up may help to increase the filling rate of medications after AMI.
- 26 February 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 117 (8) , 1028-1036
Prevalence, Predictors, and Outcomes of Primary Nonadherence After Acute Myocardial Infarction
Background— Secondary prevention after acute myocardial infarction (AMI) is achieved primarily through medications. However, patients must take their medications to benefit. Medication adherence research has focused primarily on continuation of medications rather than not filling the first prescription written (primary nonadherence). Our objectives were to characterize, to determine factors of, and to measure outcomes associated with primary nonadherence after AMI. Methods and Results— We conducted a population-based cohort study using an AMI registry linked with administrative data in Ontario, Canada. The primary outcome was 1-year mortality. There were 4591 post-AMI patients >65 years of age included with 12 832 prescriptions written, of which 73% and 79% were filled within 7 and 120 days, respectively. By 120 days after discharge, more cardiac than noncardiac prescriptions were filled (82% versus 35%, respectively; P P =0.001) and none versus all (odds ratio, 1.80; 95% confidence interval, 1.35 to 2.42; P Conclusions— Patients fill most of their discharge prescriptions within 1 week after AMI. The 1-year mortality rate was higher for those patients who did not fill all of their discharge medications after AMI. Factors such as discharge medication counseling and postdischarge follow-up may help to increase the filling rate of medications after AMI.
- 24 July 2006
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 16 (2) , 207-215
Concordance between discharge prescriptions and insurance claims in post‐myocardial infarction patients
Purpose To assess the degree of concordance between the information (drug quantity, days' supply, and daily dose) recorded on hospital discharge prescriptions and what appears in a public drug insurance electronic claims database. Methods A retrospective chart audit of hospital discharge prescriptions with linkage to a prescription claims database was conducted. Three hundred and forty‐five post‐myocardial infarction patients discharged from an Ontario university‐affiliated teaching hospital were included. The percentage of linkable records with perfect agreement between the written prescription and the insurance claim was our measure of concordance. Results Seventy‐seven per cent and 82% of discharge prescriptions were filled within 7 days, and 120 days post‐discharge, respectively. Of those dispensed and that contained adequate information, concordance was perfect for days' supply, quantity, and daily dose for 70.7% (95%CI 67.9–73.4%), 65.9% (95%CI 63.2–68.7%), and 75.9% (95%CI 73.2–78.6%) of prescriptions, respectively. For cardiac drugs, which comprised the majority of filled prescriptions, concordance was greater for daily dose and days' supply than for quantity (75.7% [95%CI 72.7–78.6%] and 75.5% [95%CI 72.6–78.4%] vs. 65.3% [95%CI 62.3–68.4%]). Concordance varied by medication type. Conclusion Most hospital discharge prescriptions were filled within 1 week. Among the data elements studied, concordance between written prescriptions and insurance claims was greatest for daily dose. Concordance was greater for scheduled cardiac medications than for other medications. Copyright © 2006 John Wiley & Sons, Ltd.
- 24 July 2006
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 16 (2) , 207-215
Concordance between discharge prescriptions and insurance claims in post‐myocardial infarction patients
Purpose To assess the degree of concordance between the information (drug quantity, days' supply, and daily dose) recorded on hospital discharge prescriptions and what appears in a public drug insurance electronic claims database. Methods A retrospective chart audit of hospital discharge prescriptions with linkage to a prescription claims database was conducted. Three hundred and forty‐five post‐myocardial infarction patients discharged from an Ontario university‐affiliated teaching hospital were included. The percentage of linkable records with perfect agreement between the written prescription and the insurance claim was our measure of concordance. Results Seventy‐seven per cent and 82% of discharge prescriptions were filled within 7 days, and 120 days post‐discharge, respectively. Of those dispensed and that contained adequate information, concordance was perfect for days' supply, quantity, and daily dose for 70.7% (95%CI 67.9–73.4%), 65.9% (95%CI 63.2–68.7%), and 75.9% (95%CI 73.2–78.6%) of prescriptions, respectively. For cardiac drugs, which comprised the majority of filled prescriptions, concordance was greater for daily dose and days' supply than for quantity (75.7% [95%CI 72.7–78.6%] and 75.5% [95%CI 72.6–78.4%] vs. 65.3% [95%CI 62.3–68.4%]). Concordance varied by medication type. Conclusion Most hospital discharge prescriptions were filled within 1 week. Among the data elements studied, concordance between written prescriptions and insurance claims was greatest for daily dose. Concordance was greater for scheduled cardiac medications than for other medications. Copyright © 2006 John Wiley & Sons, Ltd.
- 1 February 2005
- Vol. 21 (2) , 145-52
Acute treatment of myocardial infarction in Canada 1999-2002.
Therapy for management of acute myocardial infarction (AMI) varies according to patient, prescriber and geographical characteristics. To describe the in-hospital use of reperfusion therapy for ST elevation MI (STEMI) and discharge use of acetylsalicylic acid, beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs) and statins in patients presenting with either STEMI or non-STEMI in Canada from 1999 to 2002. Four Canadian registries (FASTRAK II, Canadian Acute Coronary Syndromes, Enhanced Feedback for Effective Cardiac Treatment and Improving Cardiovascular Outcomes in Nova Scotia) were used to identify patients with AMI in Canada and to measure in-hospital reperfusion and medication use. Use rates were compared by age, sex, time period and geographical area, according to available data. Use rates for reperfusion in STEMI patients ranged from 60% to 70%, primarily representing fibrinolytic therapy. A delay in presentation to hospital after symptom onset represented an impediment to timely therapy, which was particularly pronounced for women and elderly patients. Overall, less than 50% of patients met the door-to-needle target of less than 30 min. Medication use rates at discharge increased from 1999/2000 to 2000/2001 across the different data sources: acetylsalicylic acid, 83% to 88%; beta-blockers, 74% to 89%; ACEIs, 54% to 67%; statins, 41% to 53%; and calcium antagonists, 21% to 32%. Canadian and provincial rates of use of evidence-based medications for the treatment of AMI have increased over time, although there remains room for improvement. A single, comprehensive data source would supply better insights into the management of AMI in Canada.
- 1 February 2005
- Vol. 21 (2) , 145-52
Acute treatment of myocardial infarction in Canada 1999-2002.
Therapy for management of acute myocardial infarction (AMI) varies according to patient, prescriber and geographical characteristics. To describe the in-hospital use of reperfusion therapy for ST elevation MI (STEMI) and discharge use of acetylsalicylic acid, beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs) and statins in patients presenting with either STEMI or non-STEMI in Canada from 1999 to 2002. Four Canadian registries (FASTRAK II, Canadian Acute Coronary Syndromes, Enhanced Feedback for Effective Cardiac Treatment and Improving Cardiovascular Outcomes in Nova Scotia) were used to identify patients with AMI in Canada and to measure in-hospital reperfusion and medication use. Use rates were compared by age, sex, time period and geographical area, according to available data. Use rates for reperfusion in STEMI patients ranged from 60% to 70%, primarily representing fibrinolytic therapy. A delay in presentation to hospital after symptom onset represented an impediment to timely therapy, which was particularly pronounced for women and elderly patients. Overall, less than 50% of patients met the door-to-needle target of less than 30 min. Medication use rates at discharge increased from 1999/2000 to 2000/2001 across the different data sources: acetylsalicylic acid, 83% to 88%; beta-blockers, 74% to 89%; ACEIs, 54% to 67%; statins, 41% to 53%; and calcium antagonists, 21% to 32%. Canadian and provincial rates of use of evidence-based medications for the treatment of AMI have increased over time, although there remains room for improvement. A single, comprehensive data source would supply better insights into the management of AMI in Canada.
- 1 January 2005
- Vol. 21 (1) , 27-32
Routine use of glycoprotein IIb/IIIa inhibitor therapy is associated with an improved in-hospital outcome after percutaneous coronary intervention: Insights from a large, prospective, single-centre registry.
Clinical trials have demonstrated the benefit of glycoprotein IIb/IIIa inhibitors (GPIs) with stenting in the setting of percutaneous coronary intervention (PCI) in reducing adverse cardiac outcomes. To assess the association between a strategy of routine GPI use and the prevention of adverse cardiac outcomes post-PCI at a large, tertiary care institution. Patients who underwent a first PCI at the institution from April 1994 to February 2001 were divided into three cohorts: pre-GPI with selected stent use (P1), selected GPI with routine stent use (P2), and routine GPI with routine stent use (P3). A multiple logistic regression model was constructed to evaluate the different strategy periods, with the rate of in-hospital myocardial infarction, death and abrupt closure as the primary composite end point. The cohort comprised 7702 patients (2621, 3501 and 1580 patients in P1, P2 and P3, respectively). GPI use increased from 0% in P1 to 17.5% in P2 to 91.0% in P3. There was a significant difference in the unadjusted composite end point among the three periods (4.9%, 3.4% and 2.6%, for P1, P2 and P3, respectively; P<0.001). In the multiple regression analysis, the composite end point was significantly greater in P1 and P2 than in P3 (P1 versus P3, OR 2.61, P<0.0001; P2 versus P3, OR 1.55; P=0.0204). A significant reduction in adverse in-hospital clinical cardiac events was observed in association with the strategy of routine use of GPI therapy and stenting in a large, consecutive PCI cohort after adjusting for potentially confounding patient characteristics.
- 1 January 2005
- Vol. 21 (1) , 27-32
Routine use of glycoprotein IIb/IIIa inhibitor therapy is associated with an improved in-hospital outcome after percutaneous coronary intervention: Insights from a large, prospective, single-centre registry.
Clinical trials have demonstrated the benefit of glycoprotein IIb/IIIa inhibitors (GPIs) with stenting in the setting of percutaneous coronary intervention (PCI) in reducing adverse cardiac outcomes. To assess the association between a strategy of routine GPI use and the prevention of adverse cardiac outcomes post-PCI at a large, tertiary care institution. Patients who underwent a first PCI at the institution from April 1994 to February 2001 were divided into three cohorts: pre-GPI with selected stent use (P1), selected GPI with routine stent use (P2), and routine GPI with routine stent use (P3). A multiple logistic regression model was constructed to evaluate the different strategy periods, with the rate of in-hospital myocardial infarction, death and abrupt closure as the primary composite end point. The cohort comprised 7702 patients (2621, 3501 and 1580 patients in P1, P2 and P3, respectively). GPI use increased from 0% in P1 to 17.5% in P2 to 91.0% in P3. There was a significant difference in the unadjusted composite end point among the three periods (4.9%, 3.4% and 2.6%, for P1, P2 and P3, respectively; P<0.001). In the multiple regression analysis, the composite end point was significantly greater in P1 and P2 than in P3 (P1 versus P3, OR 2.61, P<0.0001; P2 versus P3, OR 1.55; P=0.0204). A significant reduction in adverse in-hospital clinical cardiac events was observed in association with the strategy of routine use of GPI therapy and stenting in a large, consecutive PCI cohort after adjusting for potentially confounding patient characteristics.
- Open Access
- 25 August 2004
- Published by Springer Nature in BMC Women's Health
- Vol. 4 (S1) , S23
Perimenopausal and Postmenopausal Health
HEALTH ISSUE: The average age of natural menopause in Western societies is estimated to be 51 years; women in Canada can therefore expect to live, on average, a third of their lives in post-menopausal years. During these years women are at increased risk of chronic diseases such as osteoporosis and cardiovascular disease. KEY FINDINGS: Clinical and epidemiological data on women in perimenopause are limited. There are no adequate Canadian data on symptom severity and prevalence among perimenopausal and postmenopausal women. Scientific evidence is lacking to support or refute claims that commonly used botanical products can offer therapeutic relief of menopausal symptoms.Recent data from the Women's Health Initiative suggest that combined estrogen plus therapy increases the risk of stroke, coronary artery disease and breast cancer. Hormone therapy is no longer recommended for the prevention of chronic diseases for asymptomatic women. Stroke is an important issue for perimenopausal and postmenopausal women and sex differences may exist in the progestin treatment of stroke. Osteoporosis affects an estimated one in six women over the age of 50. DATA GAPS AND RECOMMENDATIONS: There is a need to conduct clinical and epidemiological research aimed at better understanding the menopausal transition and defining its clinical phases. Investigations aimed at alternative combinations and doses of hormone therapy and non-pharmaceutical alternatives in light of known risks and benefits are also necessary. Health care practitioners and women need to be educated on the risks and effective treatment related to cardiovascular disease so they can present for treatment more quickly and receive the most effective therapies.
- 25 August 2004
- Published by Springer Nature in BMC Women's Health
- Vol. 4 (S1) , S23
Open AccessPerimenopausal and Postmenopausal Health
HEALTH ISSUE: The average age of natural menopause in Western societies is estimated to be 51 years; women in Canada can therefore expect to live, on average, a third of their lives in post-menopausal years. During these years women are at increased risk of chronic diseases such as osteoporosis and cardiovascular disease. KEY FINDINGS: Clinical and epidemiological data on women in perimenopause are limited. There are no adequate Canadian data on symptom severity and prevalence among perimenopausal and postmenopausal women. Scientific evidence is lacking to support or refute claims that commonly used botanical products can offer therapeutic relief of menopausal symptoms.Recent data from the Women's Health Initiative suggest that combined estrogen plus therapy increases the risk of stroke, coronary artery disease and breast cancer. Hormone therapy is no longer recommended for the prevention of chronic diseases for asymptomatic women. Stroke is an important issue for perimenopausal and postmenopausal women and sex differences may exist in the progestin treatment of stroke. Osteoporosis affects an estimated one in six women over the age of 50. DATA GAPS AND RECOMMENDATIONS: There is a need to conduct clinical and epidemiological research aimed at better understanding the menopausal transition and defining its clinical phases. Investigations aimed at alternative combinations and doses of hormone therapy and non-pharmaceutical alternatives in light of known risks and benefits are also necessary. Health care practitioners and women need to be educated on the risks and effective treatment related to cardiovascular disease so they can present for treatment more quickly and receive the most effective therapies.
- 1 November 2003
- Vol. 19 (12) , 1359-1366
Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001
BACKGROUND: There is increasing interest in studying trends in drug utilization because drug costs are the fastest growing sector of the health care system. OBJECTIVES: To focus on the trends in the utilization of and expenditures for cardiovascular drugs in Canada by drug class and by province over a six,year period. METHODS: Data from the IMS Health Canada CompuScript Audit database were used for this study from the period of February 1996 to January 2002. Patterns of drug utilization and expenditures in Canada were described for cardiovascular drug classes, individual agents within classes and by provincial analyses. RESULTS: Substantial increases in both the utilization of and the expenditures for cardiovascular medications have Occurred in Canada over the last six years. Newer medication classes such as angiotensin converting enzyme inhibitors and statins now comprise the majority of cardiovascular drugs prescribed, along with continued high use of diuretics. Increases in some drug classes, such as angiotensin converting enzyme inhibitors, statins and beta-blockers, appear to be based on trial evidence or guidelines. However, marketing may play a larger role in the increases in use of angiotensin receptor blockers and specific drugs, such as amlodipine besylate and atorvastatin, because their increased utilization cannot be explained by major clinical trial evidence and/or practice guidelines. CONCLUSIONS: Changes in patterns of cardiovascular drug utilization and expenditures in Canada may be associated with clinical trial evidence, clinical practice guidelines, policy changes and/or marketing initiatives.
- 1 November 2003
- Vol. 19 (12) , 1359-1366
Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001
BACKGROUND: There is increasing interest in studying trends in drug utilization because drug costs are the fastest growing sector of the health care system. OBJECTIVES: To focus on the trends in the utilization of and expenditures for cardiovascular drugs in Canada by drug class and by province over a six,year period. METHODS: Data from the IMS Health Canada CompuScript Audit database were used for this study from the period of February 1996 to January 2002. Patterns of drug utilization and expenditures in Canada were described for cardiovascular drug classes, individual agents within classes and by provincial analyses. RESULTS: Substantial increases in both the utilization of and the expenditures for cardiovascular medications have Occurred in Canada over the last six years. Newer medication classes such as angiotensin converting enzyme inhibitors and statins now comprise the majority of cardiovascular drugs prescribed, along with continued high use of diuretics. Increases in some drug classes, such as angiotensin converting enzyme inhibitors, statins and beta-blockers, appear to be based on trial evidence or guidelines. However, marketing may play a larger role in the increases in use of angiotensin receptor blockers and specific drugs, such as amlodipine besylate and atorvastatin, because their increased utilization cannot be explained by major clinical trial evidence and/or practice guidelines. CONCLUSIONS: Changes in patterns of cardiovascular drug utilization and expenditures in Canada may be associated with clinical trial evidence, clinical practice guidelines, policy changes and/or marketing initiatives.
- Top Cited PapersOpen Access
- 24 July 2002
- Published by American Medical Association (AMA) in JAMA
- Vol. 288 (4) , 462-467
Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes
Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors) have been shown to significantly reduce morbidity and mortality in patients with coronary artery disease (CAD) and in patients with hyperlipidemia but only if taken on a regular basis.1-5 In clinical trials, statins demonstrated benefit only after 1 to 2 years of continuous treatment. Although the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study6 showed some early benefits in acute coronary syndromes (ACSs), benefits were on nonfatal outcomes only and the absolute effect was modest. Thus, for both primary and secondary prevention, statins are intended to be used long-term to achieve their full benefit. In addition, withdrawal of statins in ACSs may increase cardiovascular event rates.7
- 24 July 2002
- Published by American Medical Association (AMA) in JAMA
- Vol. 288 (4) , 462-467
Top Cited PapersOpen AccessAdherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes
Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors) have been shown to significantly reduce morbidity and mortality in patients with coronary artery disease (CAD) and in patients with hyperlipidemia but only if taken on a regular basis.1-5 In clinical trials, statins demonstrated benefit only after 1 to 2 years of continuous treatment. Although the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study6 showed some early benefits in acute coronary syndromes (ACSs), benefits were on nonfatal outcomes only and the absolute effect was modest. Thus, for both primary and secondary prevention, statins are intended to be used long-term to achieve their full benefit. In addition, withdrawal of statins in ACSs may increase cardiovascular event rates.7
- Open Access
- 22 January 2001
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 161 (2) , 183-188
Use of the Statins in Patients After Acute Myocardial Infarction
THE SCANDINAVIAN Simvastatin Survival Study (4S),1 published in 1994, was the first large, randomized, clinical trial to demonstrate that lipid lowering with simvastatin resulted in a clear and substantial decrease in total mortality and in fewer coronary heart disease events and less cardiovascular mortality when used in patients with coronary heart disease (history of angina or myocardial infarction) who also had high low-density lipoprotein cholesterol levels. Subsequent trials2,3 have reaffirmed these initial findings.
- 22 January 2001
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 161 (2) , 183-188
Open AccessUse of the Statins in Patients After Acute Myocardial Infarction
THE SCANDINAVIAN Simvastatin Survival Study (4S),1 published in 1994, was the first large, randomized, clinical trial to demonstrate that lipid lowering with simvastatin resulted in a clear and substantial decrease in total mortality and in fewer coronary heart disease events and less cardiovascular mortality when used in patients with coronary heart disease (history of angina or myocardial infarction) who also had high low-density lipoprotein cholesterol levels. Subsequent trials2,3 have reaffirmed these initial findings.